2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106024A
    Alagebrium bromide 181069-80-7 98%
    Alagebrium bromide is an analog of Alagebrium Chloride (HY-106024B), a glucose cross-link blocker. Alagebrium Chloride disrupts glucose cross-links and may improve ventricular and arterial compliance. Alagebrium Chloride improves left ventricular diastolic filling and has the potential to inhibit diastolic heart failure (DHF).
    Alagebrium bromide
  • HY-106045A
    Imazodan hydrochloride 89198-09-4 98%
    Imazodan hydrochloride is the hydrochloride form of Imazodan (HY-106045). Imazodan hydrochloride is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan hydrochloride serves also as a peripheral vasodilator.
    Imazodan hydrochloride
  • HY-106162A
    ONO-1714 214479-33-1 98%
    ONO-1714 is an orally active nitric oxide synthase inhibitor. ONO-1714 attenuates endotoxin-induced acute lung injury, reduces intestinal ischemia–reperfusion injury, represses biliary carcinogenesis.
    ONO-1714
  • HY-106200A
    CJ-13,610 hydrochloride 179420-27-0 98%
    CJ-13,610 (hydrochloride) is an orally active and potent nonredox-type 5-lipoxygenase inhibitor with an IC50 value of 0.07 μM. CJ-13,610 (hydrochloride) competes with activating LOOH at a regulatory LOOH-binding site with high affinity, thereby preventing 5-lipoxygenase catalysis. CJ-13,610 (hydrochloride) is promising for research of diseases related to elevated levels of 5-lipoxygenase such as inflammatory reactions, allergic asthma, various types of cancer and atherosclerosis.
    CJ-13,610 hydrochloride
  • HY-106418A
    SGB-1534 hydrochloride 88068-72-8 98%
    SGB-1534 (hydrochloride) is an orally active, selective and competitive antagonist of the alpha 1-adrenoceptor and the 5-HT2 receptor. SGB-1534 (hydrochloride) can inhibit vasoconstriction and lower blood pressure. SGB-1534 (hydrochloride) can be used for the research of cardiovascular disease, such as hypertension.
    SGB-1534 hydrochloride
  • HY-106684A
    Ridazolol hydrochloride 83394-57-4 98%
    Ridazolol hydrochloride is a β-adrenergic receptor (βAR) antagonist. Ridazolol hydrochloride exhibits a high degree of selectivity for β-1 adrenergic receptor (β1AR) and possesses moderate intrinsic sympathomimetic activity (ISA). Ridazolol hydrochloride can competitively antagonize the relaxation effects induced by isoproterenol. Ridazolol hydrochloride is utilized in the research of cardiovascular diseases.
    Ridazolol hydrochloride
  • HY-106810A
    Naltiazem hydrochloride 108383-96-6 98%
    Naltiazem (Ro 23-6152) hydrochloride is a thiazepinone-type calcium antagonist. Naltiazem hydrochloride inhibits platelet aggregation in vitro and in vivo.
    Naltiazem hydrochloride
  • HY-106818A
    Monatepil maleate 103379-03-9 98%
    Monatepil maleate (AJ-2615) is a potent and orally active Ca2+-channel antagonist and a noncompetitive ACAT inhibitor. Monatepil maleate decreases blood pressure and improves plasma lipid metabolism. Monatepil maleate has the potential for the research of hyperlipidemia.
    Monatepil maleate
  • HY-106819A
    AN-132 phosphate 105668-70-0 98%
    AN-132 (phosphate) is an antiarrhythmic agent. AN-132 (phosphate) can inhibit Sodium Channel. AN-132 (phosphate) can prolong atrioventricular conduction time, decrease sinus rate and reduce the force of papillary muscle contraction. AN-132 (phosphate) can be used for the research of cardiovascular disease.
    AN-132 phosphate
  • HY-106829A
    OPC 8490 123941-50-4 98%
    OPC 8490 is a stimulant. OPC 8490 has a positive inotropic effect. OPC 8490 can be used for research on heart failure.
    OPC 8490
  • HY-106832A
    Vatanidipine hydrochloride 133743-71-2 98%
    Vatanidipine (Watanidipine) hydrochloride is an orally active dihydropyridine (DHP)-type calcium channel blocker and a useful antihypertensive agent. Vatanidipine hydrochloride shows vasodilatory effects and also suppresses noradrenaline release from sympathetic nerve endings.
    Vatanidipine hydrochloride
  • HY-106895A
    L-702958 hydrochloride 136078-58-5 98%
    L-702958 (hydrochloride) is a potent hERG blocker (IC50 = 14.3 nM). L-702958 (hydrochloride) can be used for research on arrhythmia.
    L-702958 hydrochloride
  • HY-106909A
    YM114 153608-99-2 98%
    YM114 (KAE-393) is a highly potent and selective (5-HT)3-receptor antagonist that does not affect Veratridine (HY-N6691)- or electrical stimulation-induced bradycardia in anesthetized rats. YM114 inhibits 2-methyl-5-HT (HY-19358)-induced Bezold-Jarisch reflex, which originates from (5-HT)3-receptor located on the endings of vagal afferent nerves in the heart.
    YM114
  • HY-106912A
    L-706000 free base 161799-18-4 98%
    L-706000 (MK 499) free base is a potent hERG channel blocker with an IC50 of 32 nM. L-706000 free base is a class III antiarrhythmic agent that can be used for the study of malignant ventricular tachyarrhythmias.
    L-706000 free base
  • HY-106969A
    ZD 9379 sodium 170142-29-7 98%
    ZD 9379 sodium is a competitive glycine/NMDA receptor antagonist, with an IC50 value of 75 nM (glutamate site). ZD 9379 sodium selectively antagonizes the glycine binding site (GlyB site) on the NMDA receptor, inhibiting the binding of glycine to the NMDA receptor and alleviating excitotoxicity. ZD 9379 sodium reduces the frequency of cortical spreading depression (SDs), alleviates energy depletion in the ischemic penumbra, and delays the expansion of infarction. ZD 9379 sodium reduces the infarct volume and improves neurological function in mouse models. ZD 9379 sodium can be used in studies of acute ischemic stroke, etc.
    ZD 9379 sodium
  • HY-107010A
    Esprolol hydrochloride 112805-65-9 98%
    Esprolol hydrochloride is an orally active and potent β-adrenergic receptor antagonist. Esprolol hydrochloride undergoes rapid metabolism by blood and tissue esterases to form an active metabolite, amoxolol. Esprolol hydrochloride is promising for research of exertional angina.
    Esprolol hydrochloride
  • HY-107326A
    Bunazosin hydrochloride 52712-76-2 98%
    Bunazosin hydrochloride is a potent and selective α1-adrenoceptor antagonist. Bunazosin hydrochloride can be used for antihypertensive and ocular hypotensive research.
    Bunazosin hydrochloride
  • HY-107327S
    Carazolol-d7 1173021-02-7 99.0%
    Carazolol-d7 is the deuterium labeled Carazolol (HY-107327). Carazolol is a highly potent antagonist of β1/β2 adrenoceptor. Carazolol is also a potent, selective β3-adrenoceptor agonist. Carazolol can be used in the research of hypertension.
    Carazolol-d7
  • HY-107337S
    Delapril-d3 hydrochloride 2714473-25-1 98%
    Delapril-d3 (hydrochloride) is the deuterium labeled Delapril hydrochloride. Delapril hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor for the treatment of cardiovascular diseases.
    Delapril-d3 hydrochloride
  • HY-107339A
    Deserpidine hydrochloride 6033-69-8 98%
    Deserpidine hydrochloride (Harmonyl hydrochloride) is an antihypertensive compound that competitively inhibits the activity of angiotensin converting enzyme (ACE). Deserpidine hydrochloride competes with angiotensin I for ACE, preventing the conversion of angiotensin I to angiotensin II, thereby lowering blood pressure. Deserpidine hydrochloride can also reduce angiotensin II-induced aldosterone secretion from the adrenal cortex.
    Deserpidine hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity